OUTFLOWGEN LLC
OutFlowGen: One-Time CRISPR Therapy for Glaucoma
OutFlowGen: One-Time CRISPR Therapy for Glaucoma is a funding opportunity from OUTFLOWGEN LLC, up to 311049, closing May 31, 2027.
May 31, 2027
(306d left)Overview
ABSTRACT / SUMMARY Glaucoma is the leading cause of irreversible blindness, driven in most patients by elevated intraocular pressure (IOP) from increased resistance in the eye’s drainage tissue, the trabecular meshwork (TM). While IOP-lowering eye drops help, real-world adherence is poor, side effects are common,…